Skip to content
Screener

Viridian Therapeutics, Inc. VRDN Q1 2026 earnings

Reported May 5, 2026 · Before market open

Revenue$141.0KBeat by $104.9K
EPS-$0.90Beat by $0.16
Revenue estimate$36.1K
EPS estimate-$1.06

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$4.0M
EPS estimate-$0.99

Financials

Q1 2026

Income statement

See full
Revenue$141.0K+95.8%
Operating income-$116.2M-23.8%
Net income-$104.9M-20.7%

Balance sheet

See full
Cash & equivalents$176.3M+51.7%
Total debt$36.8M+59.4%
Total equity$636.0M+5.2%
Total assets$789.0M+19.4%

Cash flow

See full
Operating cash flow-$119.7M-29.1%
CapEx$23.0K-73.3%
Free cash flow-$119.7M-29.0%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$2B+82.0%
Enterprise value$1.86B+85.0%
P/S28.2×-3,609×

Profitability

See full
Operating margin-543.9%-271pp
Net margin-508.5%-254pp
FCF margin-428.4%-214pp

Returns & leverage

See full
Return on equity-58.1%+7.9pp
Debt / equity0.1×0.0×
Current ratio15.1×-4.3×

FAQ

When did Viridian Therapeutics, Inc. report Q1 2026 earnings?
Viridian Therapeutics, Inc. (VRDN) reported Q1 2026 earnings on May 5, 2026 before market open.
What were Viridian Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Viridian Therapeutics, Inc. reported revenue of $141.0K and eps of $-0.90 for Q1 2026.
Did Viridian Therapeutics, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $36.1K by $104.9K. EPS beat the consensus estimate of $-1.06 by $0.16.
How did Viridian Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 95.8% from $72.0K a year earlier and eps declined 3.4% from $-0.87.
Where can I find Viridian Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-205010) and the 10-Q periodic report (0001590750-26-000012) directly on SEC EDGAR. The filing index links above go to sec.gov.